Therapeutic Effects of Aldose Reductase Inhibitor on Experimental Diabetic Neuropathy through Synthesis/Secretion of Nerve Growth Factor

By Ohi T.   Saita K.   Furukawa S.   Ohta M.   Hayashi K.   Matsukura S.  

Experimental Neurology, Vol. 151, Iss. 2, 1998-06 ,pp. : 215-220

Elsevier

Access to resources Recommend Favorite

Clinical trial of aldose reductase inhibitor (Epalrestat) in diabetic polyneuropathy: electrophysiological evaluation

By Katayama M.   Kaji R.   Kohara N.   Kojima Y.   Hirota N.   Kubori T.   Shibasaki H.   Kimura J.  

Electroencephalography and Clinical Neurophysiology/ Electromyography and Motor Control, Vol. 97, Iss. 4, 1995-09 ,pp. : 81-81

Elsevier

Access to resources Recommend Favorite

The Absence of Synergism between the Effects of an Aldose Reductase Inhibitor, Epalrestat, and a Vasodilator, Cilostazol, on the Nerve Conduction Slowing and the Myelinated Fiber Atrophy in Streptozotocin-Induced Diabetic Rats

By Sasaki H.   Naka K.   Kishi Y.   Furuta M.   Sanke T.   Mukoyama M.   Nanjo K.  

Experimental Neurology, Vol. 146, Iss. 2, 1997-08 ,pp. : 466-470

Elsevier

Access to resources Recommend Favorite

Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress

By Song Z.   Fu D.T.W.   Chan Y.-S.   Leung S.   Chung S.S.M.   Chung S.K.  

Molecular and Cellular Neuroscience, Vol. 23, Iss. 4, 2003-08 ,pp. : 638-647

Elsevier

Access to resources Recommend Favorite

Nonarteritic anterior ischemic optic neuropathy associated with coexisting factor V Leiden and methylenetetrahydrofolate reductase mutations

By Brouzas Dimitrios   Charakidas Antonios   Andrioti Evangelia   Koukoulomatis Pavlos   Moschos Michael  

Neuro-Ophthalmology, Vol. 26, Iss. 3, 2002-10 ,pp. : 201-204

Informa Healthcare

Access to resources Recommend Favorite